Pour la sixième année consecutive Bilan a dévoilé le 1er mars dernier (en exclusivité pour les lecteurs du magazine) sa selection de 50 start-up suisses pour investir ou s’inspirer. Avec 141 start-up présélectionnées par la rédaction de Bilan et nos partenaires ( BioAlps, CleantechAlps, AlpICT, la FONGIT et CIMARK, InnoSuisse, InnoVaud, MassChallenge, Neode, Kickstart Accelerator ainsi que Startupticker), le cru 2018 aboutit à un renouvellement à 98% des jeunes pousses choisies par le jury (voir sa composition ci-dessous). Place donc à la découverte et à la qualité.
STALICLA SA’s CEO Lynn Durham will be part of the panel at the Neurotech Investing & Partnering Conference taking place on May 1st in Boston, USA. The ‘Targeting Orphan Diseases’ panel which Lynn is a part of, will take place at 3:40pm Tuesday May 1st.
SACHS Biocapital USA Forum taking place on 21st March at the New York Academy of Sciences, USA. We are delighted to announce that CEO Lynn Durham will deliver a presentation showcasing STALICLA’s innovative approach and development pipeline, at 11:20am. In addition, Lynn will also be a part of the of the ‘Renewed Approaches for Neuroscience’ panel, which will be held at 11:45am. The Plenary panel is likely to be a highly anticipated session where Lynn will be discussing the hot topic of advanced therapeutics alongside other biotech and pharmaceutical leaders.
STALICLA selected among the 2018 top 50 start-ups in Switzerland.
STALICLA announced today that Lynn Durham, CEO and Founder, is scheduled to present at the 11th SACHS Associates 11th Annual Life Sciences CEO Forum being held February 26-27 in Zurich, Switzerland.
STALICLA is proud to announce the successful closure of its initial round of financing at CHF 4M, committed from Biotech experienced investors. This round of funding will be used to advance STALICLA’s therapeutic towards clinical trial, as well as advancing ASD research using the innovative DEPI technology. With this investment, STALICLA is also looking to expand the team in order to support the ongoing research and future commercialization of identified therapeutics.
STALICLA is proud to announce its selection on JPM UK Private Bank start-up ticket. Lynn Durham, CEO and Founder, is scheduled to present to the Healthcare Executive team during the 36th Annual JPM Healthcare conference, being held January 8-11, 2018 in San Francisco. Lynn’s presentation on the company’s strategy and development pipeline will take place on Tuesday 9th of January 2018 at 14:00 pm EST, 6th floor Westin St-Francis room.
STALICLA is excited to announce a long-term research partnership with the Greenwood Genetic Center (GGC), a leading translational research center for neurodevelopmental disorders, including autism spectrum disorder (ASD).
Lynn Durham, CEO & Founder, is participating in patient focused Drug Development meeting organized by FDA being held May 4, 2017.